Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. Karyopharm is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.

Employee Rating

Parent CompanyBiogen
HQNewton, MA, US
Cybersecurity ratingBMore
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, MA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Karyopharm Therapeutics

Garen Bohlin

Garen Bohlin

Richard Paulson

Richard Paulson

President and Chief Executive Officer, Director
Brian Austad

Brian Austad

Senior Vice President, Pharmaceutical Sciences
Mikael Dolsten

Mikael Dolsten

Sharon Shacham

Sharon Shacham

Co-Founder, Chief Scientific Officer
Michael G. Kauffman

Michael G. Kauffman

Co-Founder, Senior Clinical Advisor
Show more

Karyopharm Therapeutics Office Locations

Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo
Newton, MA, US (HQ)
85 Wells Ave
München, DE
9 Franziska-Bilek-Weg
Tel Aviv-Yafo, IL
Yigal Alon St 94
Show all (3)

Karyopharm Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$248.7 m


Karyopharm Therapeutics is a subsidiary of Biogen

Karyopharm Therapeutics Revenue

Karyopharm Therapeutics's revenue was reported to be $108.09 m in FY, 2020
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020



Revenue growth, %


General and administrative expense


R&D expense

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021



Cost of goods sold


Gross profit


Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020



Accounts Receivable


Prepaid Expenses



USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021



Accounts Receivable


Prepaid Expenses



USDQ3, 2013

Financial Leverage

-1.2 x
Show all financial metrics

Karyopharm Therapeutics Operating Metrics

FY, 2015

Patents Issued

Show all operating metrics

Karyopharm Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Karyopharm Therapeutics Online and Social Media Presence

Embed Graph

Karyopharm Therapeutics Company Culture

  • Overall Culture



  • CEO Rating



  • Compensation



  • Diversity



Learn more on Comparably

Karyopharm Therapeutics News and Updates

Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%-- --Patients with mCR had longer mOS than patients without mCR or with PD-- SHANGHAI and HONG KONG, June 8, 2021 /PRNewswire/ -- Antengene's Partner, Karyopharm...

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

SHANGHAI and HONG KONG, Dec. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc....

KARYOPHARM DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

New York, NY - (NewMediaWire) - September 20, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a fede…

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm

NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all investors that purchased Karyopharm, Inc. (NASDAQ: KPTI) securities...

ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - KPTI

NEW YORK, Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the...

KARYOPHARM SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI

NEW ORLEANS, July 26, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against...
Show more

Karyopharm Therapeutics Frequently Asked Questions

  • When was Karyopharm Therapeutics founded?

    Karyopharm Therapeutics was founded in 2008.

  • Who are Karyopharm Therapeutics key executives?

    Karyopharm Therapeutics's key executives are Garen Bohlin, Richard Paulson and Brian Austad.

  • How many employees does Karyopharm Therapeutics have?

    Karyopharm Therapeutics has 487 employees.

  • What is Karyopharm Therapeutics revenue?

    Latest Karyopharm Therapeutics annual revenue is $108.1 m.

  • What is Karyopharm Therapeutics revenue per employee?

    Latest Karyopharm Therapeutics revenue per employee is $221.9 k.

  • Who are Karyopharm Therapeutics competitors?

    Competitors of Karyopharm Therapeutics include Halozyme Therapeutics, Jiangsu Hansoh Pharmaceutical Group and Ethypharm.

  • Where is Karyopharm Therapeutics headquarters?

    Karyopharm Therapeutics headquarters is located at 85 Wells Ave, Newton.

  • Where are Karyopharm Therapeutics offices?

    Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo.

  • How many offices does Karyopharm Therapeutics have?

    Karyopharm Therapeutics has 3 offices.